

		INSTRUCTIO	NS.				
Complete this reporting form for AEFIs which have a temporal association with a vaccine and which cannot be clearly attributed to other causes. For Temporal Reporting Criteria by Event see Section H, Page 6 of this form.							
Public health staff: Enter into Panorama or PARIS.						Panorama Data Entry Guidance	
Community vaccine providers: Submit the completed form to public health. See the AEFI reporting map here for							
directions on where to send the form according to health authority. • For additional information on reporting criteria, clinical management and interpretation of AEFIs, and implications						More details in Section I, page 7.	
for subsequent immunization, plea							
REPORTER INFORMATION							
Setting: Physician office Public	health 🔲	Hospital [Other, sp	ecify:			
Name:		Phone Numb	er: ()	-	ext.	Reporter is the health
Last First		Fay Number					care provider who received and reported
Email: Address:		Fax Number	(Branch Of) fice:	<u> </u>		the AEFI information to the health unit.
Address.			(if applicable)				Defaults to the logged
Province/Territory: Posta	l code:		Date repor	rted:	YYYY/MM/DD		in user. To change, select 'Find' and
Signature:		□ MD □ R	N IMP	ACT 🗆 F	Pharmacist	, specify:	search by last name.
Reported to public health unit by: R	eporter \square	Client	Other, com	plete sec	tion A.		
A. SOURCE OF INFORMATION							
Only complete Section A if "Other" selected	ed for "Reporte	ed to public hea	alth unit by"				
Name:		Phone Number	er: ()	-	ext.	
Last First Email:		Relationship t	o client:	,			Source of information can be the same as
Address:		reciationship t	o onont.				reporter, the client, or a secondary source such as a parent/guardian.
Unit # Stree	et#		Street	Name		City	as a parent/guardian.
Postal Code:		Prov	ince:				
B. CLIENT INFORMATION							
Name:							
Date of Birth:	First Gender:	□ Male	□ Fer	mala	Middle ☐ Transgende	r 🗆 Unknown	_
YYYY/MM/DD	Gender.					- Olikilowii	4
Health Card Number:		А	Iternate Na	me(s):			Record or review and update in >Subject
Phone Number (home/work/mobile): ()	-		E	ext.		>>Client Details >>Personal
Address: Unit # S	treet #		Street Nar	~		City	Information
Postal Code: Provi		Co			(if not Canada):	Спу	Enter IMPACT Local Inventory Number if
Address Located on Reserve Administered	ed By:				_		the report was received from
ADVERSE EVENT ID:		IMPACT LIN:			PARIS ID:		IMPACT; otherwise leave it blank.
PATIENT'S PHYSICIAN (OR PRIMARY CARE	PROVIDER)						
Name:		Phone Numb	per ()	-	ext.	
Last First							4
Address:							



								Panorama Data Entry Guidance
C. IMMUNIZATION	ON DATA							
Immunizing agent	Trade name	Manufacturer	Lot numbe	er Dose#	Dosage/unit	Route	Site	An immunization record is required to create an AEFI report.
								If the immunization record has not been entered in Panorama, you will first need to create it.
								Refer to the Panorama Immunization Data Entry Guide on how to create a new immunization record.
D. INFORMATIC	N AT TIME OF I	MMUNIZATION	AND AEFI	ONSET	1			
Province/Territory of	immunization:		Age	at onset:				
Date vaccine admini	stered:	YYYY/MM/DD	(hr:		am /	pm)		Use the section specific comment
Health Care Provide	r who administered	the vaccine:	Phor	ne: ()			fields to report details in Panorama.
Address:	# Street #		Street Name			City		Please refer to Panorama AEFI Data Entry Guide for more information on the
Did an AEFI follow		-	e immunizir		ed in section B? provide details in	,		types of details to report. If there is no medical
Did this AEFI follow ☐ No ☐ Unknown ☐ Civen sutside		hoose all that apply	/ and provideroduct expire		tion G.): exceeded that re	oommondod	for ago	history relevant to this event, enter "No medical history found" in comments (No. 17).
☐ Wrong vaccing		_	correct rout			commended	ioi age	Report "Unknown at
Medical history (up	to time of AEFI on:	set). Check all that	apply and p	rovide details in	n section G.			time of report" or "Information not
☐ Concomitant med	lication(s)	☐ Known medic	al conditions	s/allergies	☐ Acute illne	ss/injury		available" in comment field No. 17.
☐ Unknown at time		☐ Information n						
(*) should be di	agnosed by a phys	ections as appropria ician. If not, provid clinical details and	e sufficient i	information to s	s/symptoms that upport the selec	t apply. Item(ted item(s). I	s) with asterisk Jse Section G	
Local reaction at or	near injection sit	e						Select a local reaction before selecting
Onset: M	lin. Hrs.	Days from im	munization	to onset of 1 st s	symptom/sign			corresponding descriptors.
Duration: M	in. Hrs.	Days from 1 st	symptom/s	ign to resolution	n of all symptom	s/signs [☐ Unresolved	For tips on reporting rash see Section I.
☐ Infected abscess	° □ Ste	rile abscess*		Cellulitis*	☐ Nodule	☐ Rash		Report 'localized rash at the injection site' as
☐ Pain, redness, or	swelling extends p	ast the nearest joir	nt 🗆 A	Adenopathy/Lyn	nphadenitis*			"Other, specify" and select "Rash" as a
☐ Pain or redness o	or swelling persistin	g for 10 days or mo	ore 🗆 C	Other, specify:				sign.
For any injection si				_				For tips on reporting pain, redness, or swelling see Section I.
☐ Swelling ☐ Specify largest diam			Erythema	☐ Warmt	th \square Induaction (e.g.,. LA,			Report 'Adenopathy/ Lymphadenitis' as
□ Palpable fluctuan		Fluid collection sh						'Lymphadenitis'.
☐ Spontaneous/surg		Microbial results,	•	ung technique ☐ Lymphangitic	, , , , ,	,	nphadenopathy	Specify Microbial results in comment box (No. 23).



		Panorama Data
		Entry Guidance
E. AEFI DETAIL	S continued	
Anaphylaxis and	other allergic events	Select "Anaphylaxis" or "Other allergic
Onset:	Min. Hrs. Days from immunization to onset of 1 st symptom/sign	events" before selecting
	Min. Hrs. Days from 1 st symptom/sign to resolution of all symptoms/signs ☐ Unresolved	corresponding
☐ Anaphylaxis	☐ Oculo-Respiratory Syndrome (ORS) ☐ Other allergic events	descriptors
For the event ind	icated above, select all symptoms/signs that apply.	For tips on reporting rash see Section I.
Skin/mucosal:	☐ Generalized: ☐ At injection site ☐ Non-injection site ☐ Urticaria ☐ Erythema	"Oculo-Respiratory
	☐ Pruritus ☐ Prickly sensation ☐ Rash	Syndrome" and associated descriptors
	☐ Localized: ☐ At injection site ☐ Non-injection site ☐ Urticaria ☐ Erythema	reported under "Other severe or unusual
	☐ Pruritus ☐ Prickly sensation ☐ Rash	events".
	Eye(s):	Report "Angioedema > Face" as
	Angioedema:	"Angioedema > Other,
	· · ·	specify". Use comment field
Cardiovascular:	☐ Eyelids ☐ Face ☐ Limbs ☐ Other, specify:	No. 34 for additional signs or symptoms
Cardiovascular.	☐ Measured hypotension ☐↓ central pulse volume ☐ Capillary refill time >3 sec ☐ Tachycardia	that are anaphylactic/ allergic in nature and
	□ ↓ or loss of consciousness:	are not listed (i.e.,
Respiratory:	☐ Sneezing ☐ Rhinorrhea ☐ Hoarse voice ☐ Sensation of throat closure ☐ Stridor	sore throat, difficulty swallowing, difficulty
	□ Dry cough □ Tachypnea □ Wheezing □ Increased use of accessory muscles	breathing, chest tightness, increased
	\square Indrawing/retractions \square Grunting \square Cyanosis \square Sore throat	use of accessory muscles, MCT
	☐ Difficulty swallowing ☐ Difficulty breathing ☐ Chest tightness	elevation).
Gastrointestinal:	☐ Diarrhea ☐ Abdominal pain ☐ Nausea ☐ Vomiting	If a client only reports GI symptoms, report
Laboratory:	☐ Mast cell tryptase elevation > upper normal limit	under "Other severe or unusual events".
Neurologic event		
Onset:	Min. Hrs. Days from immunization to onset of 1 st symptom/sign	
Duration:	Min. Hrs. Days from 1 st symptom/sign to resolution of all symptoms/signs ☐ Unresolved	First select the neurological event,
	eck all that apply):	and then choose corresponding
☐ Febrile	□ Afebrile □ Unknown type	descriptors.
☐ Focal	2 Alebilie 2 Clintiown type	Report "Myoclonic" or
☐ Generalize	ed: □Tonic □ Clonic □ Tonic-clonic □ Atonic □ Myoclonic □ Absence	"Absence" seizure as "Other neurologic
		diagnosis, specify".
	l by health care professional: □ Yes □ No □ Unknown ss of consciousness: □ Yes □ No □ Unknown	Report "Myelitis/Transverse
	nistory of seizures: Febrile Afebrile Unknown type	myelitis, ADEM or SSPE" as "Other
	☐ Encephalopathy/Encephalitis* ☐ Guillain-Barre Syndrome (GBS)* ☐ Bell's Palsy*	neurological diagnosis, specify"
☐ Anaesthesia/F	araesthesia (Check all that apply):	
☐ Generaliz	ed 🗆 Localized	Report "Anaesthesia/ Paraesthesia" and
☐ Numbnes	s 🗆 Tingling 🗆 Burning 🗆 Formication 🗆 Other, specify:	associated descriptors as "Other neurological
☐ Other paralysi	s □ Other neurological diagnosis, specify:	diagnosis, specify"
For any neurolog	ical event indicated above, check all that apply and provide details in section G.	Report Vaccine- associate Paralytic
☐ Depressed/alte	red level of consciousness/Lethargy/ Personality change lasting ≥24 hrs	Poliomyelitis as "Other paralysis"
☐ Focal or multifo	ical neurologic sign(s) ☐ Fever (≥38°C) ☐ CSF abnormality ☐ EEG abnormality	
	ity	



					Panorama Data
					Entry Guidance
E. AEFI DETAILS continued					
Other defined events of interest					
Onset: Min. Hrs.	Days from imm	unization to	onset of 1 st symptom/sign		
Duration: Min. Hrs.	Days from 1 st sy	ymptom/sig	n to resolution of all symptoms	signs Unresolved	
☐ Hypotonic-Hyporesponsive Epi	sode* (age <2 years):				
☐ Limpness ☐ Pallor/cyano	sis Reduced res	sponsivenes	ss/unresponsiveness		For tips on reporting
☐ Persistent crying (continuous an	d unaltered crying for ≥3	3 hours)			rash see Section I.
☐ Rash: (Refer to Immunization Manual	, Section IX for reporting cri	iteria. For ras	h at injection site or rash in allergic	reaction, use sections above.)	Report:
	at non-injection site				"Severe vomiting/
□ Intussusception*					diarrhea", "Orchitis", "Hematochezia", or
☐ Hematochezia					"Syncope with injury"
☐ Arthritis*: ☐ Joint redness ☐ Joint warm	to touch □ Joint sw	ollina 🗆	Inflammatory changes in synov	ial fluid	as "Other severe
☐ Parotitis* (Parotid gland swelling		•	illianimatory changes in synor	riai iiuiu	events" and specify in comment field No. 58
☐ Orchitis*	with pain and/or tenden	1033)			Report "Petechial
☐ Thrombocytopenia*:					rash" in comment
☐ Platelet count <150×10 ⁹ /L	☐ Petechial rash ☐	☐ Other clin	nical evidence of bleeding		section No. 58.
☐ Fever ≥38°C (Report only if fever			•	ent use section above.)	
☐ Syncope with injury					
☐ Severe vomiting/diarrhea					
☐ Other serious or unexpected ev	ent(s) not listed above	(Specify and	d provide details in section G):		
E. IMPACT OF AEFI, OUTCO	ME, AND LEVEL OF	CARE OF	BTAINED		
Highest impact of AEFI (Choose or	ne of the following):	Outcome	at time of report (Choose one	of the following):	
☐ Did not interfere with daily acti	ivities	☐ Pei	rmanent disability/incapacity	☐ Fully recovered	See Section I if outcome is fatal.
☐ Interfered but did not prevent	daily activities		t yet recovered	☐ Unknown	Report assessment in
☐ Prevented daily activities		☐ Dea	ath; specify date:		an emergency room setting without formal
			YYYY/MM/DD		admission to hospital
Highest level of care obtained (Ch				_	as "Emergency Visit".
☐ Emergency visit ☐ Non-ur	gent visit	one advice	from a health professional	None Unknown	Date fields for admission and
☐ Admitted to Hospital (days) OR \square Resulte	ed in prolono	gation of existing hospitalization	(by days)	discharge are visible
Hospital name:					when "Admitted to Hospital" or "Resulted
Hospital admission date:	F	Hospital disc	charge date:		in prolongation" are selected. Otherwise
Y	YYY/MM/DD		YYYY/MM/DD		enter dates of care in
Treatment received: ☐ No ☐ Un	known ☐ Yes (If yes ,	provide det	ails of treatment, including self	treatments, in section G.)	comment field No. 63.
F. PUBLIC HEALTH RECOM	MENDATIONS (Provid	de commen	ts. Use section G if extra space	is required.)	
☐ No change to immunization sched			eferral, specify:		
☐ Determine protective antibody lev		'	ed setting for next immunization	specify:	
☐ No further immunizations, specify	•		llow up for AEFI recurrence after	' '	See Section I for tips on the "Assigned to"
☐ Other, specify:			nmendations	i floxt vaccine, specify.	section.
				:6	
Name:	Professional status: L		HO ☐ MD ☐ RN ☐ Other	, specify:	Leave "Last Review Date" and "Eligible for
Comments:					reporting to PHAC" blank.
					Select "On behalf of
					Health Service
					Provider" if the user is entering the
Phone: () ext.	Date		Signature:		recommendations on
, , ,	YYYY/MM,	/ DD	2.3		behalf of another provider.
Send a copy to: ☐ BCCDC ☐	l .	Other:	I		-
Cond a copy to. BCCDC	Oliciti 3 i-Tiyaicidii 🗆	Julei			

Version Date: August 9, 2017



G.	SUPPLEMENTARY INFORMATION Please indicate the section number when providing details. Provide details of any investigation or treatment for the recorded AEFI. Provide sufficient information to support the selected item(s). Append information on additional pages if required.	
		In Panorama enter the comments into the AEFI details section of the reaction type, ie. Local, Allergic, etc. using the section-specific comment fields.



H. ADVERSE EVENTS FOLLOWING IMMUNIZATION - TEMPORAL CRITERIA

The length of time between vaccine administration and onset of symptoms is an important consideration in causality assessment. Temporal criteria guidelines in this table are generally agreed upon approximate timelines.

Reaction	Advance Event Falleville - Immunitation	Temporal Criteria		
Туре	Adverse Event Following Immunization	Inactivated Vaccines	Live Attenuated Vaccines	
ions at Site	Infected Abscess	0-7 days		
	Sterile Abscess	0-7 days		
tion (Cellulitis	0-7	days	
Local Reactions at Injection Site	Nodule	0-7 days		
	Pain or Redness or Swelling	0-48 hours		
	Adenopathy/Lymphadenopathy	0-7 days	MMR: 5 - 30 days Varicella: 5 - 42 days	
	Fever	Timing in conjunction with ot	her reportable adverse events	
tions	Hypotonic-Hyporesponsive Episode (HHE)	0-48	hours	
Зеасі	Parotitis	Not applicable	MMR: 5-30 days	
mic F	Orchitis	Not applicable	MMR: 5-30 days	
Systemic Reactions	Rash	0-7 days	MMR: 0 - 30 days Varicella: 0 - 42 days	
	Screaming/Persistent crying	0-72 hours		
	Severe Vomiting/Diarrhea	0-72 hours	Rotavirus: 0-7 days	
su us	Anaphylaxis	0-24 hours		
Allergic Reactions	Oculo-respiratory Syndrome (ORS)	0-24 hours		
& ₽	Other Allergic Reactions	0-48 hours		
	Anaesthesia/Paraethesia	0-15 days	MMR: 0 - 30 days Varicella: 0 - 42 days	
	Bell's Palsy	0-3 m	nonths	
ents	Convulsion/Seizure	0-72 hours	MMR: 5 - 30 days Varicella: 5 - 42 days	
Neurological Events	Encephalopathy or Encephalitis or Acute Disseminated Encephalomyelitis (ADEM)	0-42 days	MMR: 5 - 30 days Varicella: 5 - 42 days	
ologic	Guillain-Barré syndrome (GBS)	0-8 weeks		
Veuro	Meningitis	0-15 days	MMR: 5 - 30 days Varicella: 5 - 42 days	
_	Subacute sclerosing panencephalitis (SSPE)	Not applicable	Up to 10 years following a measles- containing vaccine	
	Paralysis	0-15 days	OPV: 5 - 30 days Varicella: 5-42 days	
Other Events of Interest	Arthritis	0-30 days	MMR: 5 - 30 days Varicella: 0 - 42 days	
	Intussusception or Haematochezia	Not applicable	Rotavirus: 0-42 days	
	Syncope with injury	0-30 minutes		
	Thrombocytopenia	0-30 days		
J	Other severe or unusual	A temporal association to immunization and for which there is no other known cause and not covered under the other categories		

Page 6 of 7 Version Date: August 9, 2017



I. PANORAMA DATA ENTRY DETAILS

Localized rash at the injection site: Local reaction at or near injection site > Other, Specify > Rash

Localized allergic rash: Anaphylaxis and other allergic events > Skin/mucosal > Localized > Select "At injection site" or "Non-injection site" > Specify rash in comment field No. 34

Generalized allergic rash: Anaphylaxis and other allergic events > Skin/mucosal > Generalized > Select "At injection site" and/or "Non-injection site" > Specify rash in comment field No. 34

Generalized rash: Other defined events of interest > Rash > Generalized

Localized rash at non-injection site: Other defined events of interest > Rash > Localized a non-injection site

Pain, redness, or swelling only reportable if meets one or both of the following:

- A) Pain, redness, or swelling extends past the nearest joint
- B) Pain or redness or swelling persists 10 days or more

Report A) as: Local reaction at or near injection site > Reaction crosses joint > Select appropriate symptoms. Report B) as: Local reaction at or near injection site > Other local, specify > Select appropriate symptoms.

Also ensure that Duration and Highest Impact of AEFI are provided.

If the outcome is fatal, record as follows.

Outcome at time of report: Death

Outcome Date: Date of death (if known) or date at which user found out about fatal outcome (if date of death unknown) Also enter date of death in client's demographics in Panorama.

After recording the outcome, inactivate the client in the Personal Information screen (under Subject > Client Details on the left hand navigation) following routine procedures/standards.

Section 10.0 'Assigned to'

The "Assigned to" section must be submitted in order to move to the "11.0 Public Health Recommendations" section. See Panorama AEFI Data Entry Guide for more information.

If the medical health officer requires a consultation from BCCDC Immunization Programs and Vaccine Preventable Diseases Service, email Dr. Monika Naus (monika.naus@bccdc.ca) and include the client ID and Adverse Event ID in your email; do not use the 'assigned to' function within Panorama for this purpose.

NOTE: Additional relevant training materials and data standards are available on the Panorama Solution Partner Portal (https://panoramacst.gov.bc.ca).

Version Date: August 9, 2017 Page 7 of 7